Akebia halts VOICE trial citing improved safety for Vafseo over ESAs
USRC and Akebia halted the VOICE trial due to improved safety outcomes with Vafseo compared to ESAs. The interim data indicates a significant reduction in hospitalizations, supporting the clinical profile of the anemia therapy.
View filing at SEC.gov →